Total Payments
$779,494
2024 Payments
$191,860
Companies
36
Transactions
905
Medicare Patients
969
Medicare Billing
$121,355
Payment Breakdown by Category
Other$679,212 (87.1%)
Consulting$40,463 (5.2%)
Travel$40,153 (5.2%)
Food & Beverage$19,643 (2.5%)
Education$23.14 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $412,212 | 129 | 52.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $165,960 | 61 | 21.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $91,800 | 37 | 11.8% |
| Consulting Fee | $40,463 | 18 | 5.2% |
| Travel and Lodging | $40,153 | 239 | 5.2% |
| Food and Beverage | $19,643 | 403 | 2.5% |
| Honoraria | $9,240 | 15 | 1.2% |
| Education | $23.14 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Intercept Pharmaceuticals, Inc. | $304,416 | 306 | $0 (2024) |
| ABBVIE INC. | $235,015 | 233 | $0 (2024) |
| Gilead Sciences, Inc. | $148,235 | 190 | $0 (2024) |
| Madrigal Pharmaceuticals | $42,664 | 40 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $38,660 | 24 | $0 (2024) |
| GlaxoSmithKline, LLC. | $2,600 | 1 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $2,275 | 9 | $0 (2024) |
| FUJIFILM Medical Systems USA, Inc. | $1,050 | 1 | $0 (2020) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $846.17 | 46 | $0 (2024) |
| Sirtex Medical Inc | $586.13 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $191,860 | 184 | Intercept Pharmaceuticals, Inc. ($56,318) |
| 2023 | $73,693 | 102 | INTERCEPT PHARMACEUTICALS, INC. ($39,063) |
| 2022 | $80,921 | 90 | INTERCEPT PHARMACEUTICALS, INC. ($41,766) |
| 2021 | $111,686 | 111 | Intercept Pharmaceuticals, Inc. ($64,414) |
| 2020 | $43,272 | 52 | AbbVie Inc. ($22,728) |
| 2019 | $125,158 | 149 | AbbVie, Inc. ($47,867) |
| 2018 | $90,004 | 103 | AbbVie, Inc. ($36,211) |
| 2017 | $62,900 | 114 | AbbVie, Inc. ($31,313) |
All Payment Transactions
905 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $11.79 | General |
| Category: Gastroenterology | ||||||
| 12/19/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: CRITICAL CARE | ||||||
| 12/18/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Travel and Lodging | In-kind items and services | $156.78 | General |
| Category: INFLAM | ||||||
| 12/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.03 | General |
| 12/17/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,940.00 | General |
| Category: INFLAM | ||||||
| 12/17/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $49.58 | General |
| Category: HCV | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $134.96 | General |
| Category: INFLAM | ||||||
| 12/12/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,887.00 | General |
| Category: Rare Disease | ||||||
| 12/12/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Travel and Lodging | In-kind items and services | $343.03 | General |
| Category: Rare Disease | ||||||
| 12/12/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $118.32 | General |
| Category: Rare Disease | ||||||
| 12/11/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,790.00 | General |
| Category: HCV | ||||||
| 12/11/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $34.66 | General |
| Category: LIVER DISEASE | ||||||
| 12/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: Gastroenterology | ||||||
| 12/09/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $31.92 | General |
| Category: HCV | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $124.42 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $16.08 | General |
| Category: LIVER DISEASE | ||||||
| 12/04/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: Rare Disease | ||||||
| 11/25/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,878.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/25/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $81.07 | General |
| Category: LIVER DISEASE | ||||||
| 11/22/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Consulting Fee | Cash or cash equivalent | $4,650.00 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.62 | General |
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: Gastroenterology | ||||||
| 11/19/2024 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 11/18/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $44.89 | General |
| Category: HCV | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 202 | 294 | $95,727 | $24,467 |
| 2022 | 9 | 238 | 350 | $114,827 | $27,554 |
| 2021 | 9 | 276 | 471 | $150,479 | $38,011 |
| 2020 | 8 | 253 | 439 | $134,940 | $31,323 |
Total Patients
969
Total Services
1,554
Medicare Billing
$121,355
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 30 | 81 | $28,755 | $7,693 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 62 | 87 | $23,403 | $6,474 | 27.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 18 | 26 | $9,880 | $2,809 | 28.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 16 | 16 | $9,216 | $2,081 | 22.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 21 | 21 | $9,282 | $1,910 | 20.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 27 | $6,723 | $1,705 | 25.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 16 | $7,488 | $1,662 | 22.2% |
| 91200 | Measurement of liver stiffness | Facility | 2023 | 20 | 20 | $980.00 | $133.76 | 13.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 33 | 106 | $37,630 | $8,686 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 88 | 116 | $31,204 | $7,674 | 24.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 24 | 34 | $12,920 | $3,722 | 28.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $10,368 | $2,416 | 23.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 22 | 22 | $9,724 | $2,183 | 22.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 15 | 15 | $7,020 | $1,519 | 21.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 12 | 12 | $3,000 | $649.36 | 21.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 13 | $2,275 | $592.09 | 26.0% |
| 91200 | Measurement of liver stiffness | Facility | 2022 | 14 | 14 | $686.00 | $111.39 | 16.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 49 | 165 | $58,575 | $13,769 | 23.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 101 | 157 | $42,233 | $11,766 | 27.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 23 | 26 | $12,168 | $2,857 | 23.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 19 | 23 | $8,740 | $2,510 | 28.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $9,216 | $2,411 | 26.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 17 | 17 | $7,514 | $1,654 | 22.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 16 | 28 | $6,972 | $1,626 | 23.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 21 | 25 | $4,375 | $1,319 | 30.1% |
About Dr. Lance Stein, MD
Dr. Lance Stein, MD is a Transplant Hepatology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568558062.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lance Stein, MD has received a total of $779,494 in payments from pharmaceutical and medical device companies, with $191,860 received in 2024. These payments were reported across 905 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($412,212).
As a Medicare-enrolled provider, Stein has provided services to 969 Medicare beneficiaries, totaling 1,554 services with total Medicare billing of $121,355. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Transplant Hepatology
- Other Specialties Gastroenterology, Hepatology
- Location Atlanta, GA
- Active Since 10/04/2006
- Last Updated 09/27/2010
- Taxonomy Code 207RT0003X
- Entity Type Individual
- NPI Number 1568558062
Products in Payments
- OCALIVA (Drug) $297,577
- MAVYRET (Drug) $113,297
- Epclusa (Drug) $98,067
- Mavyret (Drug) $73,784
- REZDIFFRA (Drug) $42,299
- IQIRVO (Drug) $33,537
- Viekira (Drug) $18,164
- Livdelzi (Drug) $14,568
- Vosevi (Drug) $11,048
- OCA (Drug) $6,839
- TERLIVAZ (Drug) $2,231
- Wako HCC Biomarker(s) DCP and AFP-L3 (Device) $1,070
- XIFAXAN (Drug) $900.87
- SIR-Spheres Microspheres (Device) $586.13
- TheraSphere Y90 Glass Microspheres 10 GBq (Device) $409.94
- RESMETIROM (Drug) $365.36
- General - Therapies (Device) $169.25
- Cresemba (Drug) $100.23
- RELTONE 200 MG (Drug) $82.11
- Nexavar (Drug) $75.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.